Catalog No.
PHC43601
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human C1S (Ile438-Pro685).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
C1 esterase,Complement C1s subcomponent,C1S,Complement component 1 subcomponent s
Purification
Purified by antigen affinity column.
Accession
P09871
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Heterologous Surface Display Reveals Conserved Complement Inhibition and Functional Diversification of Borrelia burgdorferi Elp Proteins., PMID:40376887
Anti-C1s autoantibodies as complementary serologic biomarker in lupus nephritis., PMID:40132784
Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS., PMID:39774799
IgG autoantibodies in bullous pemphigoid directly induce a pathogenic MyD88-dependent pro-inflammatory response in keratinocytes., PMID:39569141
Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro., PMID:39548231
Torque Teno Virus Control by the Classical Pathway of Complement Activation-A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab., PMID:39503157
Autoimmune haemolytic anaemias., PMID:39487134
Sutimlimab for Cold Agglutinin Disease., PMID:39328891
Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients., PMID:39255718
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial., PMID:39171350
Selection and characterization of a peptide-based complement modulator targeting C1 of the innate immune system., PMID:39092440
[Cold agglutinin disease: pathology, diagnosis, and treatment]., PMID:38960651
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease., PMID:38872338
C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells., PMID:38866870
The molecular determinants of classical pathway complement inhibition by OspEF-related proteins of Borrelia burgdorferi., PMID:38552741
Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression., PMID:38487624
Complement C1s deficiency in a male Caucasian patient with systemic lupus erythematosus: a case report., PMID:38469558
Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways., PMID:38401844
Complex changes in serum protein levels in COVID-19 convalescents., PMID:38396092
Pharmacodynamics and Mechanism of Astragali Radix and Anemarrhenae Rhizoma in Treating Chronic Heart Failure by Inhibiting Complement Activation., PMID:38386515
Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease., PMID:38148014
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study., PMID:38085846
Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders., PMID:38022610
Antibody based therapeutics for autoimmune hemolytic anemia., PMID:37874225
[Novel therapeutic agents for hemolytic anemia]., PMID:37793862
Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis., PMID:37426666
[Novel anti-complement therapeutics for hemolytic anemia]., PMID:37407469
The axis of complement C1 and nucleolus in antinuclear autoimmunity., PMID:37359557
Molecular pharmacology in complement-mediated hemolytic disorders., PMID:37308291
Complement-directed therapy for cold agglutinin disease: sutimlimab., PMID:37256550
Sutimlimab for the Treatment of Cold Agglutinin Disease., PMID:37153870
Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s., PMID:37149117
An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy., PMID:37119056
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor., PMID:36661084
Complement C1s as a diagnostic marker and therapeutic target: Progress and propective., PMID:36275687
Outer surface lipoproteins from the Lyme disease spirochete exploit the molecular switch mechanism of the complement protease C1s., PMID:36183830
Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy?, PMID:36127205
Autoantibodies against Complement Classical Pathway Components C1q, C1r, C1s and C1-Inh in Patients with Lupus Nephritis., PMID:36012546
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study., PMID:35999387
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia., PMID:35973190
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?, PMID:35946351
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial., PMID:35687757
The effects of exercise on complement system proteins in humans: a systematic scoping review., PMID:35452398
Sutimlimab: First Approval., PMID:35412113
Lipoproteome screening of the Lyme disease agent identifies inhibitors of antibody-mediated complement killing., PMID:35312359
FDA approves first anti-C1s antibody, targeting innate immunity for rare anaemia., PMID:35277678
Quantitative Visualization of the Interaction between Complement Component C1 and Immunoglobulin G: The Effect of CH1 Domain Deletion., PMID:35216207
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results., PMID:35172561
Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery., PMID:34778998
Novel therapies for immune thrombocytopenia., PMID:34611885
For research use only. Not for human or drug use.
